Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Lersivirine(UK 453061) is a second-generation non-nucleoside Reverse Transcriptase inhibitor (NNRTI) under development for HIV infection therapy.
Description | Lersivirine(UK 453061) is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) under development for HIV infection therapy. |
Targets&IC50 | NNRT:119 nM (IC50) |
Synonyms | UK-453061, Lersivirine(UK 453061) |
Molecular Weight | 310.35 |
Formula | C17H18N4O2 |
CAS No. | 473921-12-9 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
DMSO: 50 mg/mL (161.11 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Lersivirine 473921-12-9 Microbiology/Virology Proteases/Proteasome Reverse Transcriptase HIV Protease HIV UK-453061 non-nucleoside reverse transcription HIV virus UK 453061 Inhibitor UK453061 Lersivirine(UK 453061) Human immunodeficiency virus inhibit resistant strain NNRTI NNRTI-resistant inhibitor